fda deadline for semaglutide As of February 21, 2025, the updated its drug shortage list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A FDA Announces Semaglutide Shortage Resolved

Although the analysis of the primary and secondary outcomes did not reveal a drugintervention interaction, the presence of a carry-over effect that is not captured by the analysis is still possible

To obtain reliable and reproducible results, it is essential to carefully review the technical documentation of the research material

LA designed the study

Antioxidants 6(4):80

Approved GLP-1 RAs Up To 2025 At present, 11 GLP RAs are approved for treating diabetes, including Exenatide, Liraglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Beinaglutide, Semaglutide, Oral semaglutide, PEG-loxenatide and Tirzepatide

Some individuals may find temporary relief with over-the-counter supplements aimed at blood sugar control and weight management